Asherson’s syndrome is rare autoimmune disorder. It is also known catastrophic antiphospholipid syndrome. An autoimmune disorder causes antibodies to attack normal cells of the body by mistake. In Asherson’s syndrome patients, abnormal antiphospholipid antibodies attack proteins and fats in the blood, specifically phospholipids.
Signs and symptoms of Asherson's syndrome incude deep vein thrombosis (DVT), pulmonary embolism (PE), complications in pregnancy, and ischemic stroke. Headaches or migraines, livedo reticularis, seizures and dementia are less common signs and symptoms. In very rare case, patients may develop memory problems, hearing loss, progressive breathlessness, depression, or psychosis. Symptoms generally appear between the ages of 20 and 50 years.
Increase in the prevalence of Asherson's syndrome worldwide is anticipated to boost the Asherson's syndrome diagnostic and treatment market during the forecast period. Lifestyle changes are also fueling the market. Rise in government prioritization of drugs for rare disorders is also likely to boost the Asherson's syndrome diagnostic and treatment market in the near future. However, lack of knowledge about Asherson's syndrome is a major restrain of the market. Dearth of health care experts in Latin America and Middle East & Africa also limit the growth of the Asherson's syndrome diagnostic and treatment market in the regions. Nevertheless, increasing government funding for diagnosis procedures is likely to offer attractive opportunities for the Asherson's syndrome diagnostic and treatment market.
The global Asherson's syndrome diagnostic and treatment market can be segmented based on treatment, diagnostic test, end-user, and region. In terms of treatment, the market can be classified into anticoagulant, corticosteroids, steroids, immunoglobulins, and plasmapheresis. Heparin is an anticoagulant drug used for the treatment of Asherson's syndrome. The main goal of Asherson's syndrome treatment is to thin the blood in order to reduce the chances of clotting. In pregnancy, doctors do not recommend Warfarin as it can cause birth defects. Intravenous immunoglobulin infusions and corticosteroids, such as prednisone, may be prescribed if the patient does not respond to aspirin, heparin, or both.
In terms of end-user, the global Asherson’s syndrome diagnostic and treatment market can be categorized into hospitals and others. The hospitals segment held a prominent share of the market in 2017.
In terms of region, the global Asherson’s syndrome diagnostic and treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for a significant share of the global market in 2017, followed by Europe and Asia Pacific. The U.S. held a major share of the market in North America in terms of revenue. The Asherson’s syndrome diagnostic and treatment market in Asia Pacific is growing rapidly due to an increase in the number of patients suffering from the disorder in the region. Asia Pacific is projected to be a highly attractive region of the Asherson’s syndrome and treatment market in the near future. This is due to the presence of emerging economies such as India and China in the region. Moreover, factors such as better health care infrastructure, economic growth, rise in the number of insurance payers, expanding and developing private health care sector, and increase in awareness among people regarding Asherson’s syndrome diagnostic and treatment are expected to propel the market in the region in the next few years. The Asherson’s syndrome diagnostic and treatment market in Latin America and Middle East & Africa is projected to expand at a moderate growth rate from 2018 to 2026.
Key players operating in the global Asherson’s syndrome diagnostic and treatment market include Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Shenzhen Techdow Pharmaceutical Co., Ltd, Baxter, B. Braun Melsungen AG, Fresenius Kabi USA, Mylan N.V., and Novartis AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.